Search results for "Cardiovascular agents"

showing 2 items of 62 documents

Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine

2016

In the last decades, many factors thought to be associated with the atherosclerotic process and cardiovascular events have been studied, and some of these have been shown to correlate with clinical outcome, such as arterial stiffness, endothelial dysfunction and immunoinflammatory markers. Arterial stiffness is an important surrogate marker that describes the capability of an artery to expand and contract in response to pressure changes. It can be assessed with different techniques, such as the evaluation of PWV and AIx. It is related to central systolic pressure and it is an independent predictor of cardiovascular morbidity and mortality in hypertensive patients, type 2 diabetes, end-stage…

medicine.medical_specialtyPathologyEndotheliumPopulation030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoverymedicineAnimalsHumansPlatelet activationEndothelial dysfunctioneducationInflammationPharmacologyeducation.field_of_studySurrogate endpointbusiness.industryCardiovascular AgentsArteriesmedicine.diseasemedicine.anatomical_structureBlood pressureCardiovascular DiseasesCardiovascular agentArterial stiffnessCardiologyEndothelium Vascularbusiness030217 neurology & neurosurgeryCurrent Pharmaceutical Design
researchProduct

Biodegradable polymer-coated thin strut sirolimus- -eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population.

2021

Background: The number of patients with diabetes mellitus (DM) presenting with coronary artery disease is increasing and accounts for more than 30% of patients undergoing percutaneous coronary interventions (PCI). The biodegradable polymer drug-eluting stents were developed to improve vascular healing. It was sought herein, to determine 1-year clinical follow-up in patients with DM treated with the thin strut biodegradable polymer-coated sirolimus-eluting stent (BP-SES) versus durable coating everolimus-eluting stent (DP-EES). Methods: Patients were retrospectively analyzed with DM were treated with either a BP-SES (ALEX™, Balton, Poland, n = 670) or a DP-EES (XIENCE™, Abbott, USA, n = 884)…

medicine.medical_specialtyPercutaneousPolymersmedicine.medical_treatmentPopulation030204 cardiovascular system & hematologyProsthesis DesignCoronary artery disease03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionInternal medicineAbsorbable ImplantsDiabetes MellitusMedicineHumansMyocardial infarctionEverolimuseducationRetrospective StudiesSirolimuseducation.field_of_studybusiness.industryStentPercutaneous coronary interventionCardiovascular AgentsDrug-Eluting StentsGeneral Medicinemedicine.diseaseInterventional CardiologySurgeryTreatment OutcomeSirolimusConventional PCICardiologyPolandCardiology and Cardiovascular Medicinebusinessmedicine.drugCardiology journal
researchProduct